Provided by Tiger Trade Technology Pte. Ltd.

Ligand Pharmaceuticals

284.10
+3.611.29%
Post-market: 284.100.00000.00%19:30 EDT
Volume:203.70K
Turnover:57.39M
Market Cap:5.66B
PE:29.26
High:285.90
Open:276.77
Low:275.60
Close:280.49
52wk High:326.63
52wk Low:160.80
Shares:19.94M
Float Shares:19.35M
Volume Ratio:1.22
T/O Rate:1.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):9.71
EPS(LYR):6.13
ROE:21.96%
ROA:3.99%
PB:5.85
PE(LYR):46.35

Loading ...

Is Ligand Pharmaceuticals (LGND) Undervalued On Its Conference Appearance?

Simply Wall St.
·
Aug 30

Ligand Targets $150-$250 Million in Annual Investments as Royalty Revenue Tops $225 Million in 2026 Guidance

Reuters
·
Aug 26

Ligand Management Participates in Wells Fargo Healthcare Conference Fireside Chat

Reuters
·
Aug 26

Reaffirmed 2026 Guidance After Strong Q2 Could Be A Game Changer For Ligand Pharmaceuticals (LGND)

Simply Wall St.
·
Aug 19

Ligand Pharmaceuticals Price Target Announced at $330.00/Share by Leerink Partners

Dow Jones
·
Aug 15

Canada's DRI Healthcare Q2 Income Rises, Helped by Milestone Events in Royalty Portfolio

Reuters
·
Aug 08

Ligand Pharmaceuticals Price Target Raised to $345.00/Share from $340.00 by RBC Capital

Dow Jones
·
Aug 08

Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), AMN Healthcare Services (AMN) and Warby Parker (WRBY)

TIPRANKS
·
Aug 08

RBC Adjusts PT on Ligand Pharmaceuticals to $345 From $340, Maintains Outperform Rating

MT Newswires Live
·
Aug 07

Ligand Pharmaceuticals (LGND) Posts Strong Q2 Results, Is The Upside Already Priced In?

Simply Wall St.
·
Aug 07

Halozyme Q2 Revenue Jumps 48%, Raises 2026 Outlook

Reuters
·
Aug 07

Ligand Pharmaceuticals is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 07

Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), Protagonist Therapeutics (PTGX) and Zoetis (ZTS)

TIPRANKS
·
Aug 07

Ligand Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $358 from $289

THOMSON REUTERS
·
Aug 06

Cancer Drugmaker Genmab's H1 Revenue Rises, Lifts FY Outlook

Reuters
·
Aug 06

Ligand Pharmaceuticals Incorporated Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Ligand Pharmaceuticals Q2 Adjusted Earnings, Revenue Rise; 2026 Adjusted EPS Outlook Lifted, Revenue Outlook Reaffirmed

MT Newswires Live
·
Aug 06

Agenus Q2 Revenue Rises on Access and Royalty Income

Reuters
·
Aug 06

GUIDANCE: (LGND) Ligand Pharmaceuticals Expects 2026 Adjusted EPS Range $9.00 to $9.50, vs. FactSet Est of $9.21

MT Newswires Live
·
Aug 06

Ligand Q2 FY26 Adjusted EPS Climbs 48% to $2.37; Revenue Rises 34% to $63.7 Million

Reuters
·
Aug 06